Andreas Hougaard Laustsen

Professor Andreas Hougaard Laustsen-Kiel heads the Section for Biologics Engineering at the Department of Biotechnology and Biomedicine at the Technical University of Denmark (DTU) and is a Group Leader for the Antibody Technologies research group. He is a leading expert in antibody technologies, specializing in the discovery of antibodies and nanobodies against toxins, as well as antibodies with microenvironment-responsive binding properties. He was the first to develop human monoclonal antibodies against animal toxins and has formulated many of the principles around the development of recombinant antivenoms. Andreas is a co-founder of several biotech companies and spinouts, including Biosyntia, VenomAb, Antag Therapeutics, Chromologics, VenomAid Diagnostics, Agrobiomics, Combotope Therapeutics, Y-king Biologics, and Bactolife, employing 120 FTEs. He received his Dr.techn. (higher doctorate) in 2026 from DTU, his PhD in 2016 from the University of Copenhagen, and his M.Sc.Eng. in 2012 from DTU. His work has been cited 6000+ times and recognized with awards such as the Silver Medal for Excellent Basic Research in 2023 (Royal Danish Academy of Sciences and Letters) and the Elite Research Award in 2025 (Danish Ministry of Higher Education and Science).